Hodgkin's Recurrence for Def Leppard Guitarist

Vivian Campbell, the rock guitarist formerly of Dio and other bands and currently a member of Def Leppard, has unfortunately announced that his Hodgkin's lymphoma has recurred.

He announced as much on his Facebook page, writing,

“I’m saddened by the fact that my cancer has returned. However, I’m beyond consolation that its return will prevent me from being able to do my job for a while. I’m still working on a schedule of treatment with my doctors, but I will see you all very soon. My apologies.”

Initially diagnosed in the summer of 2013, Campbell immediately underwent treatment and within five months was said to be in remission. A year later he underwent a stem cell transplantation when the Hodgkin's first recurred. It is believed that the transplant was Campbell's third therapy for the disease: he underwent an undisclosed frontline therapy, then (most likely, according to Campbell's statements) he was administered Adcetris, and finally the transplant, although it's possible Adcetris was administered as a consolidation therapy following the transplant.

His band, Def Leppard, is currently in the midst of preparing for a summer tour with fellow rock bands Tesla and Styx. Since Campbell will not be joining them, there's no official word yet on who will replace him for the tour.

Source: Inquisitr

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap